Highlights Phathom Pharmaceuticals, Inc.

Equities

PHAT

US71722W1071

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
9.35 ^USD	+1.85%		+3.77%	+2.41%

Mar. 07	Transcript : Phathom Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 07, 2024
Mar. 07	Phathom Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Phathom Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 07	CI
Phathom Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07	CI
Phathom Pharmaceuticals Announces Voquezna® Tablets for Erosive Gerd and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients	Feb. 13	CI
Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD	Dec. 06	CI
Phathom Pharmaceuticals, Inc. Announces Commercial Availability of VOQUEZNA®? Tablets	Nov. 28	CI
Phathom Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Phathom Pharmaceuticals, Inc. Announces FDA Approval of VOQUEZNA® Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in Adults	Nov. 01	CI
Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for Voquezna Triple Pak (Vonoprazan, Amoxicillin, Clarithromycin) and Voquezna Dual Pak (Vonoprazan, Amoxicillin) for the Treatment of H. Pylori Infection in Adults	23-10-30	CI
Phathom Pharmaceuticals Seeks FDA Nod for Vonoprazan to Treat Non-Erosive GERD in Adults	23-09-26	MT
Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive Germany	23-09-26	CI
Phathom Pharmaceuticals Submits Six-Month Stability Data to US FDA Supporting Vonoprazan for Stomach Condition	23-08-21	MT
Phathom Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Phathom Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Phathom Pharmaceuticals Sees Commercial Launch of Vonoprazan for Erosive Esophagitis, H. Pylori Indications in Q4	23-04-04	MT
Phathom Pharmaceuticals Provides Regulatory Update Following Its Recent Meeting with FDA Regarding the Complete Response Letters for Phathom's Erosive Esophagitis (EE) NDA and H. Pylori Post Approval Supplement to VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK NDAs	23-04-04	CI
PHATHOM PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	23-02-28	AQ
Phathom Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-28	CI
Phathom Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-28	CI
Phathom Pharmaceuticals Says US FDA Asks for More Stability Data on Vonoprazan Products; Shares Plunge	23-02-10	MT
Phathom Pharmaceuticals, Inc. Approves in the U.S. for the Treatment of H. Pylori Infection, and Its Pending New Drug Application for Vonoprazan for the Treatment of Erosive Esophagitis	23-02-09	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Phathom Pharmaceuticals, Inc.

Equities

PHAT

US71722W1071

Highlights

Filters